CD-123-FLT-3 BiTE

N/A

Report date: 2026/03/19 16:59:44

Base Information

Drug NameCD-123-FLT-3 BiTE

Drug Alias NameCD123-FLT3 BiTECD-123-FLT-3 BiTE

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsInterleukin-3 receptor subunit alpha inhibitors +[3]

TargetsT cell surface glycoprotein CD3Interleukin-3 receptor subunit alphaTyrosine-protein kinase receptor FLT3

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A